The hospital in a needle.
Nanocan (NANOphotonics for the fight against CANcer) is an advanced technology platform designed to enhance the diagnostic and therapeutic approaches to breast cancer and liver cancer, by combining nanotechnologies with optical fibers, thus representing an evolution from conventional medicine to personalized medicine.
The fight against cancer is one of the priority challenges to be faced in the health field, in terms of scientific research. In recent decades, improvements in diagnosis and therapy techniques, thanks to continuous technological developments, have led to a decrease in the incidence of the disease, but a definitive solution to the problem is still far from being found.
Precision medicine and personalized medicine use innovative and increasingly multidisciplinary solutions that make it possible to improve and speed up diagnoses and minimize the side effects of treatments.
The biggest challenge of the NANOCAN project is to develop a new class of devices capable of revolutionizing the techniques and approaches currently used for diagnosis and therapy in cancer. The goal is to have a tool (a medical needle) capable of simultaneously carrying out diagnosis and therapy (theranostics), to be performed, in the future, “in vivo”, inside the patient’s body. The combination of optical fibers and nanotechnologies, at the base of the international scientific literature, has made it possible to convert the fiber into a multifunctional probe capable of performing various tasks: thanks to the integration of appropriate biomaterials defined on a micro and nano-metric scale, it can be engineered to become a biosensor, a high-resolution molecular recognition tool, or a probe capable of delivering drugs in a controlled manner through light pulses.
Our added Values
Transversal skills in engineering, IT, electronics and fiber optics allow the Teoresi Group to face the bio-medical market with solutions ranging from mechanical and hardware design, to software development to control and monitor diagnostic and therapy devices, including portable ones, such as for example, tools for administering therapies ad hoc, in an innovation ecosystem that flows from biomedical to ICT and more generally to eHealth.
Furthermore, within the project consortium, Teoresi has been recognized as the entity capable of engineering the prototype, bridging the gap between research and market needs.
In this video clip the NANOCAN project is told by the protagonists: researchers, doctors, engineers, chemists and biologists of the CeRICT (Benevento) and Teoresi (Naples).
- The technologies used in the project could allow, once integrated into clinical practice, a time reduction in real time diagnostics while maintaining the possibility of performing controlled drug release actions directly on a specific site.
- Within the project consortium, Teoresi had the role of initiating engineering and patenting processes.
in three years on average